Lonza Group (OTCMKTS:LZAGY) Stock Rating Upgraded by Royal Bank Of Canada

Lonza Group (OTCMKTS:LZAGY) was upgraded by investment analysts at Royal Bank Of Canada from a “hold” rating to a “moderate buy” rating in a research report issued on Wednesday,Zacks.com reports.

Separately, Zacks Research lowered Lonza Group from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 4th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Lonza Group has a consensus rating of “Hold”.

Lonza Group Stock Performance

LZAGY opened at $64.87 on Wednesday. The company has a quick ratio of 0.87, a current ratio of 2.24 and a debt-to-equity ratio of 0.42. The business’s 50 day moving average is $67.99 and its 200-day moving average is $68.50. Lonza Group has a twelve month low of $55.57 and a twelve month high of $73.85.

Lonza Group Company Profile

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.